Evaluation of the Dietary Supplement Efficacy Against Hair Loss in Subjects Suffering From Hair Loss
Clinical Instrumental Evaluation of the Efficacy of a Dietary Supplement Claiming Anti Hair Loss Properties
1 other identifier
interventional
240
1 country
1
Brief Summary
The goal of this study was to learn if dietary supplement in capsules and drinkable works to help hair loss in volunteers with chronic telogen effluvium and androgenetic alopecia and learn about its safety. The main questions it aims to answer are:
- Does dietary supplement in capsules and drinkable reduces hair loss in women and men suffering from chronic telogen effluvium or androgenetic alopecia?
- Were the products well accepted by the subjects from their´s perspective? Researchers will compare dietary supplement in capsules and drinkable to a placebo (a look-alike substance that contains no active ingredients) to see if dietary supplements works to reduce hair loss. Participants will:
- Take assigned diatry supplement in capsule or drinkable or a placebo every day for 6 months
- Visit the study facility once every 3 months for evaulations
- Keep a diary of the product use
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 4, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 26, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 26, 2025
CompletedFirst Submitted
Initial submission to the registry
January 14, 2026
CompletedFirst Posted
Study publicly available on registry
January 22, 2026
CompletedJanuary 26, 2026
January 1, 2026
11 months
January 14, 2026
January 22, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change from Baseline in the hair density at 3 and 6 months
Pictures of chosen area of the scalp are taken and the number of hairs per cm2 is counted.
From the baseline, at 3 months and at the end of the study (6 months).
Secondary Outcomes (1)
Assessment of product acceptability and perceived efficacy at 3 and 6 months
On 3 months and 6 months of product use.
Study Arms (4)
Dietary supplement capsule
EXPERIMENTALDietary supplement capsule was taken by the subjects daily during 6 months
Dietary supplement capsule placebo
PLACEBO COMPARATORDietary supplement capsule placebo was taken by the subjects daily during 6 months
Dietary supplement drinkable
EXPERIMENTALDietary supplement drinkable was taken by the subjects daily during 6 months
Dietary supplement drinkable placebo
PLACEBO COMPARATORDietary supplement drinkable placebo was taken by the subjects daily during 6 months
Interventions
Dietary supplement capsule use for hair loss, once a day during 6 months.
Dietary supplement capsule placebo use for hair loss, once a day during 6 months.
Dietary supplement drinklable use for hair loss, once a day during 6 months.
Dietary supplement drinklable placebo use for hair loss, once a day during 6 months.
Eligibility Criteria
You may qualify if:
- Healthy female and male subjects, including at least 70% female subjects aged over 30 years old ✓ Caucasian ethnicity
- Aged between 18 and 62 years old (extreme included)
- % of subjects with chronic telogen effluvium (stage from 2 to 4, according to Sinclair scale for female pattern hair loss in women and modified Sinclair scale for female pattern hair loss in men)
- % of subjects with androgenetic alopecia (AGA): female subjects Ludwig scale (score I-II) and male subjects Hamilton- Norwood scale (vertex II-III)
- Subjects aware of the study procedures and having signed an informed consent form
- Subjects registered with National Health Service (NHS)
- Subjects certifying the truthfulness of the personal data disclosed to the investigator
- Subjects able to understand the language used in the investigation and to respect the instructions given by the investigator as well as able to respect the study constraints and specific requirements
- Commitment not to change the daily routine or the lifestyle
- Subject informed about the study procedures and having signed the privacy policy
You may not qualify if:
- Subjects with acute or chronic diseases able to interfere with the outcome of the study or that are considered dangerous for the subject or incompatible with the study requirements
- Subjects participating or planning to participate in other clinical trials
- Subjects deprived of freedom by administrative or legal decision or under guardianship
- Subjects not able to be contacted in case of emergency
- Subjects admitted to a health or social facility
- Subjects planning a hospitalization during the study
- Subjects who participated in a similar study without respecting an adequate washout period (3 months)
- Alimentary/Eating disorders (i.e., bulimia, psychogenic eating disorders, etc.)
- Food allergy or food intolerances
- Impaired immune system due to i-mmunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications
- Subjects who have any type of gastrointestinal disease or disorders (Chrons disease, colitis, irritable bowel syndrome, intestinal malabsorption)
- Pharmacological treatment (topic or systemic) known to interfere with the tested product or having effect on metabolism (e.g.: anticoagulants, antidepressants, drugs used to lower cholesterol levels, antiviral drugs and beta-blockers)
- Subjects having frequent stomach burn
- Cosmetic treatment known to interfere with the tested product (e.g.: anti-hair loss shampoo, antihair loss food supplements, anti-hair loss serum) during the study and in the last 3 months before study start
- Subjects who intends to carry out any straightening, permanent or other treatments on hair (hair botox,etc)
- +4 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Lacer S.A.lead
Study Sites (1)
Complife Italia
San Martino Siccomario, Milan, 27028, Italy
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 14, 2026
First Posted
January 22, 2026
Study Start
November 4, 2024
Primary Completion
September 26, 2025
Study Completion
September 26, 2025
Last Updated
January 26, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share
The results will be shared in the paper.